Proteome analysis revealed a significant downregulation of these proteins in Cldn1-KO cells, and subsequent functional assays demonstrated that this downregulation corresponded to reduced cancer cell proliferation, invasion, and drug resistance. The gene discussed is CLDN1; the disease is cancer.